Verano Holdings VRNO
OTC VRNO
$6.09 +0.25 (+4.28%)
At close: Aug 19, 2026 · 3:58 PM UTC

Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026)

Verano Holdings (VRNO) posted quarterly Non-Current Deferred Tax Liability of $36.7 million for Q1 2026, down 49.73% year-over-year from $73.0 million in Q1 2025, and little changed quarter-over-quarter from $36.6 million in Q4 2025.

Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $36.7 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Deferred Tax Liability fell 49.73% year-over-year to $36.7 million; the TTM figure through Mar 2026 stood at $36.7 million (down 49.73% YoY), while the FY2025 annual figure was $36.6 million, down 63.85% from the prior year.
  • Non-Current Deferred Tax Liability steadied at $36.7 million in Q1 2026 per VRNO's latest filing, from $36.6 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $259.3 million in Q2 2022 and bottomed at $2.7 million in Q1 2022.
  • Historically, Non-Current Deferred Tax Liability has averaged $140.2 million across 5 years, with a median of $174.8 million in 2024.
  • Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 26219.88% — and 2025, when it tumbled 63.85%.
  • Verano Holdings' Non-Current Deferred Tax Liability stood at $209.0 million in 2022, then fell by 12.8% to $182.2 million in 2023, then tumbled by 44.38% to $101.4 million in 2024, then sank by 63.85% to $36.6 million in 2025, then advanced by 0.11% to $36.7 million in 2026.
  • Business Quant data shows VRNO's Non-Current Deferred Tax Liability at $36.7 million in Q1 2026, $36.6 million in Q4 2025, and $71.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 44.07 Bn 43.10 Bn -
2 Teva Pharmaceutical Industries 43.41 Bn 39.75 Bn 2.15 Bn
3 Zoetis 31.83 Bn 30.15 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.77 Bn 22.97 Bn 5.10 Bn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn
6 Viatris 18.76 Bn 17.87 Bn 1.46 Bn
7 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn
8 Elanco Animal Health 11.93 Bn 11.40 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.16 Bn 10.00 Bn -
10 Verano Holdings 450.50 Mn 365.31 Mn 99.70 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 43.41 Mn
Jun 30, 2026 43.41 Mn
Mar 31, 2026 36.69 Mn
Mar 31, 2026 36.69 Mn
Dec 31, 2025 36.64 Mn
Dec 31, 2025 36.64 Mn
Sep 30, 2025 71.02 Mn
Sep 30, 2025 71.02 Mn
Jun 30, 2025 72.37 Mn
Jun 30, 2025 72.37 Mn
Mar 31, 2025 72.98 Mn
Mar 31, 2025 72.98 Mn
Dec 31, 2024 101.36 Mn
Dec 31, 2024 101.36 Mn
Sep 30, 2024 168.16 Mn
Sep 30, 2024 168.16 Mn
Jun 30, 2024 174.79 Mn
Jun 30, 2024 174.79 Mn
Mar 31, 2024 180.25 Mn
Mar 31, 2024 180.25 Mn